Vir Biotechnology (VIR) Equity Ratio (2018 - 2026)

Vir Biotechnology has disclosed Equity Ratio across 9 years of filings, most recently posting 0.79 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.79, down 0.71% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.79 (down 0.71% YoY), and the FY2025 annual result was 0.76, down 7.21% from the prior year.
• Equity Ratio came in at 0.79 for Q1 2026 at Vir Biotechnology, up from 0.76 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.86 in Q1 2024 to a low of 0.69 in Q1 2022.
• The 5-year median for Equity Ratio is 0.8 (2022), against an average of 0.79.
• Across the five-year window, Equity Ratio increased 20.91% in 2022 and retreated 7.48% in 2025, its largest moves.
• Vir Biotechnology's Equity Ratio stood at 0.74 in 2022, then increased by 11.74% to 0.83 in 2023, then decreased by 0.75% to 0.82 in 2024, then retreated by 7.21% to 0.76 in 2025, then rose by 3.85% to 0.79 in 2026.
• The last three Equity Ratio figures came in at 0.79 (Q1 2026), 0.76 (Q4 2025), and 0.78 (Q3 2025), per Business Quant data.